Amneal Pharmaceuticals, Inc. Class A (AMRX) Dividend History

Amneal Pharmaceuticals, Inc. Class A (AMRX) is a pharmaceutical company that develops, manufacturers, and distributes generic and specialty medications. Founded in 2013, it focuses on providing affordable healthcare solutions across various therapeutic areas, including CNS, dermatology, and gastrointestinal treatments. The company operates through a diverse portfolio of products and emphasizes innovation, quality, and accessibility in its offerings.

Website: https://www.amneal.com

Dividend History

Amneal Pharmaceuticals, Inc. Class A currently does not pay dividends

Company News

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?

Goldman Sachs initiated coverage on several generic pharmaceutical stocks, highlighting Teva's branded drug growth and biosimilar pipeline as positives, while expressing neutrality on Viatris due to uncertainty around its core business. The firm also initiated Amneal with a Buy rating, citing its strong product pipeline and ability to offset price erosion.

Benzinga

Featured Companies: VTRS
Global Antidote Market to Cross the USD 4 Billion Mark by 2032 | DelveInsight

The dilated cardiomyopathy market is witnessing substantial growth, driven by advancements in cardiovascular therapies and the increasing incidence of the condition. Key factors contributing to the market's upward momentum include greater public awareness, government initiatives, and continuous progress in product innovation.

GlobeNewswire Inc.

Featured Companies: AMPH
Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsight

The Parkinson's disease market is expected to grow significantly due to the introduction of emerging therapies, advancements in treatment options, and a rising prevalence of the condition.

GlobeNewswire Inc.

Featured Companies: ACAD LLY MGTX
Polycystic Ovarian Syndrome Treatment Market Set for USD 4.3 Billion by 2034 as Demand for Personalized Medicine Rises | Exclusive Report by TMR

The Polycystic Ovarian Syndrome (PCOS) Treatment Market is expected to grow significantly, driven by the rising prevalence of hormonal disorders, infertility, and metabolic complications among women. Treatment options include pharmacological therapies and non-pharmacological approaches. Advancements in personalized medicine and fertility treatments are fueling market expansion.

GlobeNewswire Inc.

Featured Companies: ABT
Glioblastoma Multiforme Treatment Market Size to Reach USD 5.68 Bn by 2033

The global glioblastoma multiforme treatment market is expected to grow from $2.78 billion in 2024 to $5.68 billion by 2033, driven by advancements in immunotherapy and research for better treatment options.

GlobeNewswire Inc.

Featured Companies: KPTI MRK PFE

Dividend data last updated 06/07/2025 16:26:44 UTC